MedPath

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

🇷🇴Romania
Ownership
Private
Employees
-
Market Cap
-
Website

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

Not Applicable
Completed
Conditions
mCRPC or Advanced/Metastatic Solid Tumors
Prostate-specific Membrane Antigen
Interventions
First Posted Date
2018-03-05
Last Posted Date
2025-01-08
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
1225
Registration Number
NCT03453528
Locations
🇮🇹

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.

Not Applicable
Recruiting
Conditions
Malignant Glioma
High Grade Glioma
Recurrent Glioma
Interventions
Device: HBO
Radiation: RT
First Posted Date
2018-01-26
Last Posted Date
2023-05-30
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
24
Registration Number
NCT03411408
Locations
🇮🇹

Centro Iperbarico, Ravenna, RA, Italy

🇮🇹

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

🇮🇹

Neuroradiology, AUSL della Romagna - RAVENNA, Ravenna, RA, Italy

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Phase 2
Terminated
Conditions
Neuroendocrine Carcinoma
Interventions
First Posted Date
2018-01-02
Last Posted Date
2025-03-10
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
53
Registration Number
NCT03387592
Locations
🇮🇹

Az. Osp. Ospedali Riuniti di Ancona, Ancona, AN, Italy

🇮🇹

A.O.U. Policlinico di Bari, Bari, BA, Italy

🇮🇹

IRCCS IST. Tumori Bari - Giovanni Paolo II, Bari, BA, Italy

and more 20 locations

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

Active, not recruiting
Conditions
Circulating Tumor Cells
Prostate Cancer
Metastatic Cancer
Castration-resistant Prostate Cancer
First Posted Date
2017-12-22
Last Posted Date
2023-06-02
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
104
Registration Number
NCT03381326
Locations
🇮🇹

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy

🇮🇹

Ospedale Civile degli Infermi, Rimini, RN, Italy

🇮🇹

Ospedali Riuniti Umberto I, Ancona, AN, Italy

and more 6 locations

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

Not Applicable
Recruiting
Conditions
Malignant Pleural Mesothelioma
Interventions
Radiation: Accelerated hypofractionation with Tomotherapy
First Posted Date
2017-08-31
Last Posted Date
2023-05-30
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
30
Registration Number
NCT03269227
Locations
🇮🇹

SC Radiotherapy, Meldola, Italy

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Phase 2
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
First Posted Date
2017-07-26
Last Posted Date
2023-05-30
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
70
Registration Number
NCT03230734
Locations
🇮🇹

U.O. Oncologia PO Vito Fazzi, Lecce, LE, Italy

🇮🇹

UO Oncologia Medica, IRST IRCCS, Meldola, FC, Italy

🇮🇹

IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy

and more 12 locations

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Phase 2
Completed
Conditions
Hormone Receptor Positive Breast Cancer
Metastatic Breast Cancer
Hormone Receptor Negative Breast Cancer
Interventions
Drug: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
Drug: chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
First Posted Date
2017-07-24
Last Posted Date
2024-11-07
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
52
Registration Number
NCT03227328
Locations
🇮🇹

A.O.U. Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Ancona, Italy

🇮🇹

U.O. Oncologia Medica; Ist. Tumori Giovanni Paolo II - IRCCS Osp. Oncologico di Bari, Bari, Italy

🇮🇹

U.O. Oncologia Medica, P.O. Bellaria-Maggiore, Bologna, BO, Italy

and more 17 locations

Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC

Phase 2
Withdrawn
Conditions
Carcinoma, Renal Cell
Vaccination
Secondary
Interventions
Radiation: boost radiotherapy (XRT)
Biological: Autologous DC vaccine
First Posted Date
2017-07-21
Last Posted Date
2018-11-13
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Registration Number
NCT03226236
Locations
🇮🇹

UO Immunoterapia e Laboratorio TCS, IRCCS IRST, Meldola (FC), FC, Italy

Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.

Not Applicable
Conditions
Cancer
Oral Drug Administration
Interventions
Device: TreC-Onco
First Posted Date
2016-10-03
Last Posted Date
2021-02-26
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
40
Registration Number
NCT02921724
Locations
🇮🇹

Irst-Irccs, Meldola (FC), Italy

🇮🇹

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Bergamo, Italy

🇮🇹

Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento, Trento, Italy

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

Not Applicable
Completed
Conditions
68Ga-PSMA HBED-PET/CT
Prostate Cancer
Interventions
Drug: 68Ga- PSMA
First Posted Date
2016-09-30
Last Posted Date
2025-01-09
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
1230
Registration Number
NCT02920229
Locations
🇮🇹

Irst Irccs, Meldola, FC, Italy

© Copyright 2025. All Rights Reserved by MedPath